JP2017501211A - 生体試料中で改善された性能を有するｉｇｆｂｐ７のためのアッセイ - Google Patents

生体試料中で改善された性能を有するｉｇｆｂｐ７のためのアッセイ Download PDF

Info

Publication number
JP2017501211A
JP2017501211A JP2016552481A JP2016552481A JP2017501211A JP 2017501211 A JP2017501211 A JP 2017501211A JP 2016552481 A JP2016552481 A JP 2016552481A JP 2016552481 A JP2016552481 A JP 2016552481A JP 2017501211 A JP2017501211 A JP 2017501211A
Authority
JP
Japan
Prior art keywords
antibody
seq
amino acid
chain variable
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2016552481A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017501211A5 (enExample
Inventor
ヴィジャエンドラン，ラヴィ，エー．
ヴェンカタスッバラオ，スリヴァスタ
Original Assignee
アスチュート メディカル，インコーポレイテッド
アスチュート メディカル，インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アスチュート メディカル，インコーポレイテッド, アスチュート メディカル，インコーポレイテッド filed Critical アスチュート メディカル，インコーポレイテッド
Publication of JP2017501211A publication Critical patent/JP2017501211A/ja
Publication of JP2017501211A5 publication Critical patent/JP2017501211A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54306—Solid-phase reaction mechanisms
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/558—Immunoassay; Biospecific binding assay; Materials therefor using diffusion or migration of antigen or antibody
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4745—Insulin-like growth factor binding protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/34—Genitourinary disorders
    • G01N2800/347—Renal failures; Glomerular diseases; Tubulointerstitial diseases, e.g. nephritic syndrome, glomerulonephritis; Renovascular diseases, e.g. renal artery occlusion, nephropathy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
JP2016552481A 2013-11-06 2014-11-06 生体試料中で改善された性能を有するｉｇｆｂｐ７のためのアッセイ Pending JP2017501211A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201361900942P 2013-11-06 2013-11-06
US61/900,942 2013-11-06
US201462054324P 2014-09-23 2014-09-23
US62/054,324 2014-09-23
US201462064380P 2014-10-15 2014-10-15
US62/064,380 2014-10-15
PCT/US2014/064327 WO2015069880A1 (en) 2013-11-06 2014-11-06 Assays for igfbp7 having improved performance in biological samples

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019212462A Division JP2020048569A (ja) 2013-11-06 2019-11-25 生体試料中で改善された性能を有するｉｇｆｂｐ７のためのアッセイ

Publications (2)

Publication Number Publication Date
JP2017501211A true JP2017501211A (ja) 2017-01-12
JP2017501211A5 JP2017501211A5 (enExample) 2017-11-24

Family

ID=53042071

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2016552481A Pending JP2017501211A (ja) 2013-11-06 2014-11-06 生体試料中で改善された性能を有するｉｇｆｂｐ７のためのアッセイ
JP2019212462A Pending JP2020048569A (ja) 2013-11-06 2019-11-25 生体試料中で改善された性能を有するｉｇｆｂｐ７のためのアッセイ
JP2022003920A Active JP7277623B2 (ja) 2013-11-06 2022-01-13 生体試料中で改善された性能を有するｉｇｆｂｐ７のためのアッセイ
JP2023000938A Pending JP2023052239A (ja) 2013-11-06 2023-01-06 生体試料中で改善された性能を有するｉｇｆｂｐ７のためのアッセイ

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2019212462A Pending JP2020048569A (ja) 2013-11-06 2019-11-25 生体試料中で改善された性能を有するｉｇｆｂｐ７のためのアッセイ
JP2022003920A Active JP7277623B2 (ja) 2013-11-06 2022-01-13 生体試料中で改善された性能を有するｉｇｆｂｐ７のためのアッセイ
JP2023000938A Pending JP2023052239A (ja) 2013-11-06 2023-01-06 生体試料中で改善された性能を有するｉｇｆｂｐ７のためのアッセイ

Country Status (12)

Country Link
US (3) US9822172B2 (enExample)
EP (2) EP3066221A4 (enExample)
JP (4) JP2017501211A (enExample)
KR (1) KR102404285B1 (enExample)
CN (1) CN105793439B (enExample)
AU (1) AU2014346695B2 (enExample)
BR (1) BR112016010106A2 (enExample)
CA (2) CA3185700A1 (enExample)
EA (1) EA201690731A1 (enExample)
HK (1) HK1221490A1 (enExample)
MX (1) MX375701B (enExample)
WO (1) WO2015069880A1 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010048346A1 (en) 2008-10-21 2010-04-29 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
MX342967B (es) 2009-12-20 2016-10-19 Astute Medical Inc Metodos y composiciones para la diagnosis y prognosis de lesion renal y falla renal.
NZ605698A (en) 2010-06-23 2015-03-27 Astute Medical Inc Methods and compositions for diagnosis and prognosis of renal injury and renal failure
EP3540440B1 (en) 2011-12-08 2022-09-28 Astute Medical, Inc. Methods and uses for evaluating renal injury and renal status
JP6681195B2 (ja) 2013-01-17 2020-04-15 アスチュート メディカル，インコーポレイテッド 腎損傷および腎不全の診断および予後診断のための方法ならびに組成物
CN110007084B (zh) 2013-12-03 2022-11-18 阿斯图特医药公司 用于肾损伤和肾衰竭的诊断和预后的方法和组合物
ES2708325T5 (es) * 2014-10-29 2023-02-17 Hoffmann La Roche Biomarcadores para la predicción del riesgo de progresión de insuficiencia cardiaca crónica y de la mortalidad
WO2016164854A1 (en) 2015-04-09 2016-10-13 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
KR102083104B1 (ko) * 2015-10-08 2020-02-28 에프. 호프만-라 로슈 아게 수술 전 측정시 ａｋｉ 의 위험 예측을 위한 ｉｇｆｂｐ７
AU2017277305A1 (en) 2016-06-06 2018-12-20 Astute Medical, Inc. Management of acute kidney injury using insulin-like growth factor-binding protein 7 and tissue inhibitor of metalloproteinase 2
CN110431422A (zh) 2017-02-06 2019-11-08 机敏医药股份有限公司 用于肾损伤和肾衰竭的诊断和预后的方法和组合物
WO2018187453A1 (en) 2017-04-05 2018-10-11 Astute Medical, Inc. Assays for timp2 having improved performance in biological samples
US11435364B2 (en) 2018-05-24 2022-09-06 Renibus Therapeutics, Inc. Methods of treating patients at risk for renal injury and renal failure
WO2020234482A1 (en) * 2019-05-21 2020-11-26 Universität Zürich MAPKi RESISTANCE SIGNATURES
KR102533791B1 (ko) * 2022-09-15 2023-05-18 경북대학교 산학협력단 비색법 신호형질 복합체, 이를 이용하는 신장질환 진단용 키트 및 진단법
EP4729541A1 (en) * 2024-10-16 2026-04-22 Paolo Fiorina Anti- igfbp7 antibodies and uses thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120045391A1 (en) * 2008-10-14 2012-02-23 National Research Council Canada Formulations Targeting IGFBP7 for Diagnosis and Therapy of Cancer

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3029579C2 (de) 1980-08-05 1985-12-12 Boehringer Mannheim Gmbh, 6800 Mannheim Verfahren und Mittel zur Abtrennung von Plasma oder Serum aus Vollblut
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5939272A (en) 1989-01-10 1999-08-17 Biosite Diagnostics Incorporated Non-competitive threshold ligand-receptor assays
US5028535A (en) 1989-01-10 1991-07-02 Biosite Diagnostics, Inc. Threshold ligand-receptor assay
US5413923A (en) 1989-07-25 1995-05-09 Cell Genesys, Inc. Homologous recombination for universal donor cells and chimeric mammalian hosts
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
EP1690935A3 (en) 1990-01-12 2008-07-30 Abgenix, Inc. Generation of xenogeneic antibodies
US5922615A (en) 1990-03-12 1999-07-13 Biosite Diagnostics Incorporated Assay devices comprising a porous capture membrane in fluid-withdrawing contact with a nonabsorbent capillary network
US5166051A (en) 1990-08-08 1992-11-24 Genesis Labs, Inc. Membranes, membrane overlays for exclusion of erythrocytes, and method for immunoassay of whole blood analytes
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
ES2246502T3 (es) 1990-08-29 2006-02-16 Genpharm International, Inc. Animales no humanos transgenicos capaces de producir anticuerpos heterologos.
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
CA2072758A1 (en) 1990-09-14 1992-03-15 Kenneth Francis Buechler Antibodies to complexes of ligand receptors and ligands and their utility in ligand-receptor assays
GB9109645D0 (en) * 1991-05-03 1991-06-26 Celltech Ltd Recombinant antibodies
US5955377A (en) 1991-02-11 1999-09-21 Biostar, Inc. Methods and kits for the amplification of thin film based assays
AU1772992A (en) 1991-04-10 1992-11-17 Biosite Diagnostics Incorporated Crosstalk inhibitors and their uses
EP0579767B1 (en) 1991-04-11 2000-08-23 Biosite Diagnostics Inc. Novel conjugates and assays for simultaneous detection of multiple ligands
EP0590058B1 (en) 1991-06-14 2003-11-26 Genentech, Inc. HUMANIZED Heregulin ANTIBODy
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
US6019944A (en) 1992-05-21 2000-02-01 Biosite Diagnostics, Inc. Diagnostic devices and apparatus for the controlled movement of reagents without membranes
US6143576A (en) 1992-05-21 2000-11-07 Biosite Diagnostics, Inc. Non-porous diagnostic devices for the controlled movement of reagents
US5494829A (en) 1992-07-31 1996-02-27 Biostar, Inc. Devices and methods for detection of an analyte based upon light interference
US5824799A (en) 1993-09-24 1998-10-20 Biosite Diagnostics Incorporated Hybrid phthalocyanine derivatives and their uses
CA2219361C (en) 1995-04-27 2012-02-28 Abgenix, Inc. Human antibodies derived from immunized xenomice
WO1996034096A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6391265B1 (en) 1996-08-26 2002-05-21 Biosite Diagnostics, Inc. Devices incorporating filters for filtering fluid samples
US6113855A (en) 1996-11-15 2000-09-05 Biosite Diagnostics, Inc. Devices comprising multiple capillarity inducing surfaces
EP1972194A1 (en) 1996-12-03 2008-09-24 Amgen Fremont Inc. Transgenic mammals having human ig loci including plural vh and vk regions and antibodies produced therefrom
US6045899A (en) 1996-12-12 2000-04-04 Usf Filtration & Separations Group, Inc. Highly assymetric, hydrophilic, microfiltration membranes having large pore diameters
US5947124A (en) 1997-03-11 1999-09-07 Biosite Diagnostics Incorporated Diagnostic for determining the time of a heart attack
US6057098A (en) 1997-04-04 2000-05-02 Biosite Diagnostics, Inc. Polyvalent display libraries
US7109030B2 (en) * 2000-03-31 2006-09-19 Nuvelo, Inc. Methods of therapy and diagnosis using insulin-like growth factor binding protein-like polypeptides and polynucleotides
US20020132983A1 (en) * 2000-11-30 2002-09-19 Junghans Richard P. Antibodies as chimeric effector cell receptors against tumor antigens
EP1880218A2 (en) 2005-04-29 2008-01-23 Beckman Coulter Fluorescence lateral flow immunoassay
SI1904104T1 (sl) * 2005-07-08 2013-12-31 Biogen Idec Ma Inc. Protitelesa SP35 in njihova uporaba
DK2115477T3 (en) * 2007-01-25 2015-08-10 Hoffmann La Roche USE OF IGFBP-7 IN THE EVIDENCE OF HEART FAILURE
BRPI1012195A2 (en) 2009-05-01 2018-04-24 Abbott Laboratories double variable domain immunoglobulins and their uses
MX342967B (es) 2009-12-20 2016-10-19 Astute Medical Inc Metodos y composiciones para la diagnosis y prognosis de lesion renal y falla renal.
CN102791885B (zh) * 2010-02-05 2015-09-09 阿斯图特医药公司 用于肾损伤和肾衰竭的诊断及预后的方法和组合物
SG10201506782XA (en) 2010-08-27 2015-10-29 Stem Centrx Inc Notum protein modulators and methods of use
BR112014010532A2 (pt) * 2011-11-03 2017-04-18 Tolera Therapeutics Inc anticorpo e métodos para inibição seletiva de respostas de célula-t

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120045391A1 (en) * 2008-10-14 2012-02-23 National Research Council Canada Formulations Targeting IGFBP7 for Diagnosis and Therapy of Cancer

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
J CLIN ENDOCRINOL METAB, APRIL 2003, 88(4):1849-1857, JPN6018032471, ISSN: 0004077733 *
J CLIN ENDOCRINOL METAB, JULY 2003, 88(7):3401-3408, JPN6018032470, ISSN: 0004077732 *

Also Published As

Publication number Publication date
KR20160068988A (ko) 2016-06-15
US10562961B2 (en) 2020-02-18
MX2016005834A (es) 2016-11-17
JP7277623B2 (ja) 2023-05-19
JP2020048569A (ja) 2020-04-02
WO2015069880A1 (en) 2015-05-14
US20160289308A1 (en) 2016-10-06
CA3185700A1 (en) 2015-05-14
EP3066221A1 (en) 2016-09-14
CA2929547C (en) 2023-02-28
US20200247879A1 (en) 2020-08-06
EP3556863B1 (en) 2024-09-18
EP3066221A4 (en) 2017-09-20
CA2929547A1 (en) 2015-05-14
JP2022068143A (ja) 2022-05-09
EA201690731A1 (ru) 2016-10-31
US9822172B2 (en) 2017-11-21
KR102404285B1 (ko) 2022-05-31
BR112016010106A2 (pt) 2017-12-05
AU2014346695A1 (en) 2016-06-16
US20180066045A1 (en) 2018-03-08
JP2023052239A (ja) 2023-04-11
AU2014346695B2 (en) 2020-10-15
MX375701B (es) 2025-03-06
CN105793439A (zh) 2016-07-20
EP3556863A1 (en) 2019-10-23
CN105793439B (zh) 2020-09-04
HK1221490A1 (zh) 2017-06-02

Similar Documents

Publication Publication Date Title
JP7277623B2 (ja) 生体試料中で改善された性能を有するｉｇｆｂｐ７のためのアッセイ
US10457744B2 (en) Assays for TIMP2 having improved performance in biological samples
US12624121B2 (en) Assays for TIMP2 having improved performance in biological samples
JP2021509120A (ja) Ｃｃｌ１４に関する抗体およびアッセイ
CN106814192B (zh) 用于肝癌检测的标志物组合及检测试剂盒
US20220356238A1 (en) Antibodies and assays for ccl14

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20171013

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20171013

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180828

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20181127

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190227

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20190723